✦ LIBER ✦

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

✍ Scribed by Stephen A. Schey; Gareth J. Morgan; Karthik Ramasamy; Beth Hazel; Dariusz Ladon; Sophie Corderoy; Matthew Jenner; Karen Phekoo; Kevin Boyd; Faith E. Davies

Book ID: 108676841
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 197 KB
Volume: 150
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2010.08250.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Phase II study of CLAD (cyclophosphamide

Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone)

✍ G. Hütter; H. Szélenyi; A. Schmittel; J. M. Siehl; E. Thiel; U. Keilholz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract The purpose of this study was to assess the efficacy and safety of pegylated liposomal doxorubicin in combination with cyclophosphamide and dexamethasone (CLAD). In this prospective open‐label phase II study, 60 patients with advanced multiple myeloma (MM) received three weekly cycles o

Phase I and II pharmacokinetic and pharm

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

✍ Yoshiaki Ogawa; Kensei Tobinai; Michinori Ogura; Kiyoshi Ando; Takahide Tsuchiya 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

Patient heterogeneity in phase II studie

Patient heterogeneity in phase II studies of refractory disease in multiple myeloma – the ‘spell’ of the time to first relapse

✍ N. Emil U. Hermansen; Peter Gimsing 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB